Cediranib

Cediranib

Clinical data
Routes of administration	Oral
Pharmacokinetic data
Elimination half-life	12 to 35 hours
Identifiers
IUPAC name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy- 7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
CompTox Dashboard (EPA)	DTXSID10183035
ECHA InfoCard	100.196.628
Chemical and physical data
Formula	C25H27FN4O3
Molar mass	450.5 g/mol g·mol−1

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.

As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.

On February 27th in 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.

Further reading

• Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. PMID 15899831. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

External links

• AZD2171—AstraZeneca Pipeline